Table 2.
Baseline characteristics according to stromal M1- and M2-like macrophage densities in the invasive margin of first resected CRC pulmonary metastases
| M1-like macrophages | M2-like macrophages | p | ||||
|---|---|---|---|---|---|---|
| Low | High | Low | High | |||
| n (%) | n (%) | n (%) | n (%) | |||
| n | 30 | 26 | 27 | 29 | ||
| Sex | > 0.999 | 0.789 | ||||
| Female | 15 (50.0%) | 13 (50.0%) | 14 (51.9%) | 14 (48.3%) | ||
| Male | 15 (50.0%) | 13 (50.0%) | 13 (48.1%) | 15 (51.7%) | ||
| Age (M; SD) | 68.27 (11.92) | 66.42 (9.16) | 0.524 | 66.93 (10.62) | 67.86 (10.88) | 0.746 |
| RCS Comorbidity Score | 0.617 | 0.548 | ||||
| 1 | 20 (66.7%) | 14 (53.8%) | 15 (55.6%) | 19 (65.5%) | ||
| 2 | 6 (20.0%) | 7 (26.9%) | 8 (29.6%) | 5 (17.2%) | ||
| ≥ 3 | 4 (13.3%) | 5 (19.2%) | 4 (14.8%) | 5 (17.2%) | ||
| Neoadjuvant chemotherapy | 0.666 | 0.446 | ||||
| No | 19 (63.3%) | 15 (57.7%) | 15 (55.6%) | 19 (65.5%) | ||
| Yes | 11 (36.7%) | 11 (42.3%) | 12 (44.4%) | 10 (34.5%) | ||
| Disease stage | 0.184 | 0.735 | ||||
| 1–2 | 10 (33.3%) | 11 (42.3%) | 9 (33.3%) | 12 (41.4%) | ||
| 3 | 15 (50.0%) | 7 (26.9%) | 12 (44.4%) | 10 (34.5%) | ||
| 4 | 5 (16.7%) | 8 (30.8%) | 6 (22.2%) | 7 (24.1%) | ||
| Primary tumour location | 0.284 | 0.789 | ||||
| Colon | 17 (56.7%) | 11 (42.3%) | 14 (51.9%) | 14 (48.3%) | ||
| Rectum | 13 (43.3%) | 15 (57.7%) | 13 (48.1%) | 15 (51.7%) | ||
| Disease-free interval (d; MD; IQR) | 675 (143–925) | 282.5 (0–763) | 0.284 | 427 (0–1004) | 314 (0–773) | 0.496 |
| Size of largest pulmonary metastasis (cm; MD; IQR) | 2.2 (1.2–3.5) | 2.5 (1.5–3.5) | 0.424 | 2 (1.2–3.5) | 2.5 (1.4–3.5) | 0.938 |
| Former liver metastases | 0.197 | 0.977 | ||||
| No | 19 (63.3%) | 12 (46.2%) | 15 (55.6%) | 16 (55.2%) | ||
| Yes | 11 (36.7%) | 14 (53.8%) | 12 (44.4%) | 13 (44.8%) | ||
| Synchronicity | 0.351 | 0.889 | ||||
| Synchronous | 5 (16.7%) | 7 (26.9%) | 6 (22.2%) | 6 (20.7%) | ||
| Metachronous | 25 (83.3%) | 19 (73.1%) | 21 (77.8%) | 23 (79.3%) | ||
| No. of pulmonary metastases | 0.337 | 0.719 | ||||
| 1 | 16 (53.3%) | 18 (69.2%) | 15 (55.6%) | 19 (65.5%) | ||
| 2 | 10 (33.3%) | 7 (26.9%) | 9 (33.3%) | 8 (27.6%) | ||
| ≥ 3 | 4 (13.3%) | 1 (3.8%) | 3 (11.1%) | 2 (6.9%) | ||
| Laterality of metastases | 0.093 | 0.889 | ||||
| Unilateral | 21 (70.0%) | 23 (88.5%) | 21 (77.8%) | 23 (79.3%) | ||
| Bilateral | 9 (30.0%) | 3 (11.5%) | 6 (22.2%) | 6 (20.7%) | ||
| BRAF | 0.935 | 0.113 | ||||
| Wild-type | 27 (96.4%) | 24 (96.0%) | 22 (91.7%) | 29 (100.0%) | ||
| Mutant | 1 (3.6%) | 1 (4.0%) | 2 (8.3%) | 0 (0.0%) | ||
RCS royal college of surgeons. The Chi-square test, Student’s T test, and Mann–Whitney U test were applied